Literature DB >> 16185263

Translating the science of quality of life into practice: What do dermatology life quality index scores mean?

Yan Hongbo1, Charles L Thomas, Michael A Harrison, M Sam Salek, Andrew Y Finlay.   

Abstract

This study's aim was to determine the relationship between Dermatology Life Quality Index (DLQI) scores and a Global Question (GQ) concerning patients' views of the overall impairment of their skin-related quality of life (QoL), and to express this relationship by identifying bands of DLQI scores equivalent to each GQ descriptor. A DLQI questionnaire and the GQ were mailed to 3834 adult general dermatology outpatients. There were 1993 (52%) responses: male 841; female 1152. Mean DLQI score = 4.86 (range 0-30, standard deviation (SD) = 5.83). Mean GQ score = 1.22 (range 0-4, SD = 1.20). The mean, mode, and median of the GQ scores for each DLQI score were used to devise several sets of bands of DLQI scores, and kappa coefficients of agreement calculated. The set proposed for adoption is: DLQI scores 0-1 = no effect on patient's life (GQ = 0, n = 754); DLQI scores 2-5 = small effect on patient's life (GQ = 1, n = 611); DLQI scores 6-10 = moderate effect on patient's life (GQ = 2, n = 327); DLQI scores 11-20 = very large effect on patient's life (GQ = 3, n = 242); DLQI scores 21-30 = extremely large effect on patient's life (GQ = 4, n = 59); kappa coefficient 0.489. Banding of the DLQI will aid the clinical interpretation of an individual's DLQI score and allow DLQI scores to inform clinical decisions.

Entities:  

Mesh:

Year:  2005        PMID: 16185263     DOI: 10.1111/j.0022-202X.2005.23621.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  137 in total

1.  Discrepancies between the Dermatology Life Quality Index and utility scores.

Authors:  Fanni Rencz; Petra Baji; László Gulácsi; Sarolta Kárpáti; Márta Péntek; Adrienn Katalin Poór; Valentin Brodszky
Journal:  Qual Life Res       Date:  2015-12-18       Impact factor: 4.147

2.  Effects of a novel formulation of fluocinonide 0.1% cream on skin barrier function in atopic dermatitis.

Authors:  Matthew T Woods; Peter A Brown; Shahana F Baig-Lewis; Eric L Simpson
Journal:  J Drugs Dermatol       Date:  2011-02       Impact factor: 2.114

3.  Otitis externa: quality of life assessment.

Authors:  R Ali; P Burns; M Donnelly
Journal:  Ir J Med Sci       Date:  2008-02-23       Impact factor: 1.568

4.  Binary outcomes are not better than continuous variables in randomized controlled trials.

Authors:  Jan Kottner; David L Streiner
Journal:  J Invest Dermatol       Date:  2013-06-11       Impact factor: 8.551

5.  Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting.

Authors:  Junko Takeshita; Shuwei Wang; Daniel B Shin; Kristina Callis Duffin; Gerald G Krueger; Robert E Kalb; Jamie D Weisman; Brian R Sperber; Michael B Stierstorfer; Bruce A Brod; Stephen M Schleicher; Andrew D Robertson; Kristin A Linn; Russell T Shinohara; Andrea B Troxel; Abby S Van Voorhees; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2014-09-24       Impact factor: 11.527

6.  Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris: A Single-Arm Trial.

Authors:  Dylan Haynes; Jennifer L Strunck; Christina A Topham; Alex G Ortega-Loayza; Gail Kent; Pamela B Cassidy; Ronghua Hu; Keith Choate; Zhiping Wang; Yuangang Liu; Teri M Greiling
Journal:  JAMA Dermatol       Date:  2020-06-01       Impact factor: 10.282

Review 7.  Psoriasis: advances in pathophysiology and management.

Authors:  A MacDonald; A D Burden
Journal:  Postgrad Med J       Date:  2007-11       Impact factor: 2.401

8.  The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures.

Authors:  Thaschawee Arkachaisri; Soamarat Vilaiyuk; Suzanne Li; Kathleen M O'Neil; Elena Pope; Gloria C Higgins; Marilynn Punaro; Egla C Rabinovich; Margalit Rosenkranz; Daniel A Kietz; Paul Rosen; Steven J Spalding; Teresa R Hennon; Kathryn S Torok; Elaine Cassidy; Thomas A Medsger
Journal:  J Rheumatol       Date:  2009-10-15       Impact factor: 4.666

9.  Interpretation of Renal Quality of Life Profile scores in routine clinical practice: an aid to treatment decision-making.

Authors:  Nadine Aawar; Richard Moore; Stephen Riley; Sam Salek
Journal:  Qual Life Res       Date:  2015-11-27       Impact factor: 4.147

10.  A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa.

Authors:  Robert A Lee; Erica Dommasch; James Treat; Joslyn Sciacca-Kirby; Samuel Chachkin; Jennifer Williams; Daniel B Shin; James J Leyden; Carmela Vittorio; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2009-01-31       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.